Current Report Filing (8-k)
28 January 2021 - 2:01PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): January 28, 2021
ORGANICELL
REGENERATIVE MEDICINE, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-55008
|
|
47-4180540
|
(State or Other Jurisdiction
|
|
(Commission File
Number)
|
|
(IRS Employer
|
of Incorporation)
|
|
|
|
Identification No.)
|
4045 Sheridan Avenue, Suite 239, Miami, FL
|
|
33140
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant's
telephone number, including area code: (888) 963-7881
(Former name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each Class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
None
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As
used in this Current Report on Form 8-K, and unless otherwise indicated, the terms “the Registrant”, “the
Company,” “Organicell,” “we,” “us” and “our”
refer to Organicell Regenerative Medicine, Inc.
Item 8.01 Other Events.
On
January 28, 2021, Organicell issued a press release in which it announced that the U.S. Food and Drug Administration (FDA) has
approved the Investigational New Drug (IND) application for its lead product, Zofin™, in the treatment of patients diagnosed
with chronic obstructive pulmonary disease (COPD).
A
copy of the Company’s press release dated January 28, 2021 is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
Item 9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated: January 28,
2021
|
ORGANICELL REGENERATIVE MEDICINE,
INC.
|
|
|
|
By:
|
/s/
Ian Bothwell
|
|
|
Ian
Bothwell
Chief Financial Officer
|